Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate : Results of a Phase III, Double‐Blind, Randomized Controlled Trial

enthalten in: Arthritis & Rheumatology | 2019

von Fleischmann, R. | Pangan, A. | Song, I. | +9

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

enthalten in: Arthritis & Rheumatology | 2018

von Mease, P. | Genovese, M. | Weinblatt, M. | +8

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

enthalten in: Arthritis & Rheumatology | 2018

von Genovese, M. | Weinblatt, M. | Aelion, J. | +8